Maravai LifeSciences (MRVI) Competitors $2.38 +0.05 (+2.15%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$2.38 0.00 (0.00%) As of 05:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRVI vs. IMVT, GMTX, RXRX, CPRX, KNSA, OGN, ALVO, CNTA, IBRX, and TARSShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Immunovant (IMVT), Gemini Therapeutics (GMTX), Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), ImmunityBio (IBRX), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Maravai LifeSciences vs. Its Competitors Immunovant Gemini Therapeutics Recursion Pharmaceuticals Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Organon & Co. Alvotech Centessa Pharmaceuticals ImmunityBio Tarsus Pharmaceuticals Immunovant (NASDAQ:IMVT) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Does the media refer more to IMVT or MRVI? In the previous week, Immunovant had 6 more articles in the media than Maravai LifeSciences. MarketBeat recorded 12 mentions for Immunovant and 6 mentions for Maravai LifeSciences. Immunovant's average media sentiment score of 1.38 beat Maravai LifeSciences' score of 1.07 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of IMVT or MRVI? 47.1% of Immunovant shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 2.1% of Maravai LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is IMVT or MRVI more profitable? Immunovant has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -90.03%. Maravai LifeSciences' return on equity of -17.60% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -80.99% -72.23% Maravai LifeSciences -90.03%-17.60%-9.30% Which has more risk and volatility, IMVT or MRVI? Immunovant has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Which has higher earnings and valuation, IMVT or MRVI? Maravai LifeSciences has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.85-5.20Maravai LifeSciences$219.83M2.76-$144.85M-$1.36-1.75 Do analysts recommend IMVT or MRVI? Immunovant currently has a consensus price target of $35.20, suggesting a potential upside of 137.52%. Maravai LifeSciences has a consensus price target of $5.22, suggesting a potential upside of 119.28%. Given Immunovant's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immunovant is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18 SummaryImmunovant and Maravai LifeSciences tied by winning 8 of the 16 factors compared between the two stocks. Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$594.99M$10.89B$5.77B$9.79BDividend YieldN/A1.87%3.95%4.02%P/E Ratio-1.7521.3931.2726.59Price / Sales2.7629.95440.26156.12Price / Cash3.7724.7837.7359.36Price / Book1.303.5110.616.68Net Income-$144.85M$210.11M$3.27B$265.59M7 Day Performance-2.86%2.14%1.41%0.62%1 Month Performance-4.03%14.27%6.20%2.61%1 Year Performance-74.16%-7.07%50.13%22.34% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences3.9863 of 5 stars$2.38+2.1%$5.22+119.3%-74.0%$594.99M$219.83M-1.75610Positive NewsIMVTImmunovant3.0135 of 5 stars$15.26+0.3%$35.20+130.7%-52.7%$2.65BN/A0.00120News CoverageGMTXGemini TherapeuticsN/A$59.86-1.4%N/A+21.2%$2.59BN/A-59.8630News CoverageRXRXRecursion Pharmaceuticals1.9646 of 5 stars$5.52-4.3%$7.00+26.8%-34.1%$2.51B$58.84M0.00400CPRXCatalyst Pharmaceuticals4.8625 of 5 stars$20.23flat$33.20+64.1%+0.0%$2.48B$491.73M12.2680Insider TradeKNSAKiniksa Pharmaceuticals International2.4584 of 5 stars$33.72+1.0%$41.17+22.1%+27.0%$2.47B$423.24M843.21220Positive NewsOGNOrganon & Co.4.8076 of 5 stars$9.27-1.8%$18.00+94.2%-59.2%$2.45B$6.40B2.674,000Positive NewsALVOAlvotech2.0296 of 5 stars$9.00+12.2%$14.00+55.6%-30.9%$2.42B$491.98M18.241,032High Trading VolumeCNTACentessa Pharmaceuticals2.7084 of 5 stars$17.59-2.5%$28.10+59.7%+22.8%$2.42B$6.85M0.00200IBRXImmunityBio2.2354 of 5 stars$2.43-4.7%$10.75+342.4%-42.6%$2.41B$14.74M0.00590Analyst ForecastTARSTarsus Pharmaceuticals1.8224 of 5 stars$54.61+0.7%$66.67+22.1%+118.8%$2.29B$182.95M0.0050Positive News Related Companies and Tools Related Companies IMVT Alternatives GMTX Alternatives RXRX Alternatives CPRX Alternatives KNSA Alternatives OGN Alternatives ALVO Alternatives CNTA Alternatives IBRX Alternatives TARS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access